A US study found that a syringe services programme is an important tool to control and prevent HIV outbreaks among people who inject drugs in a non-urban area.

ViiV Healthcare has released data from two phase 3 trials that showed a once-daily, two-drug regimen of dolutegravir and lamivudine was non-inferior to a standard three-drug regimen in treatment-naive patients with HIV.

Early, sustained antiretroviral therapy (ART), which results in long-term viral suppression, helps to prevent Aids-defining cancers and also non-Aids-defining cancers, to a lesser degree.

Predictive computer models designed to optimise HIV therapy in countries with limited healthcare resources have been published online. The models accurately predict how an individual on failing therapy will respond to any new combination of HIV drugs.

The risk of liver toxicity in people with HIV taking antiretroviral therapy and isoniazid preventive therapy for tuberculosis is strongly associated with either hepatitis B co-infection or pre-existing liver enzyme elevations, according to international research.